CTA313
/ Nanjing Bioheng Biotech
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
October 03, 2025
A Study of Anti-CD19/BCMA Universal CAR-T Cell Therapy RD06-05 in Patients With Autoimmune Diseases.
(clinicaltrials.gov)
- P1 | N=84 | Recruiting | Sponsor: Nanjing Bioheng Biotech Co., Ltd.
New P1 trial • ANCA Vasculitis • Glomerulonephritis • Immunology • Inflammatory Arthritis • Lupus Nephritis • Nephrology • Vasculitis
1 to 1
Of
1
Go to page
1